Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further milestones remain) and favorable adjustments to rebate and discount...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.